Published in Antimicrob Agents Chemother on September 14, 2009
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther (2010) 1.27
Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol (2011) 1.05
Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A (2009) 1.03
Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J Virol (2010) 1.02
Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin Pharmacol Ther (2010) 0.97
Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox). Antimicrob Agents Chemother (2013) 0.85
Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine (2010) 0.84
Development of ST-246® for Treatment of Poxvirus Infections. Viruses (2010) 0.84
Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. Future Virol (2011) 0.82
Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246. Viruses (2010) 0.78
Deletion of the K1L Gene Results in a Vaccinia Virus That Is Less Pathogenic Due to Muted Innate Immune Responses, yet Still Elicits Protective Immunity. J Virol (2017) 0.75
Extracellular Virions: The Advance Guard of Poxvirus Infections. PLoS Pathog (2015) 0.75
Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Antimicrob Agents Chemother (2015) 0.75
Antiviral therapy: a perspective. Drug Des Devel Ther (2016) 0.75
Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol (1980) 4.24
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol (2005) 3.36
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol (1992) 3.24
Diagnosis and management of smallpox. N Engl J Med (2002) 3.20
Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis (2003) 2.46
Virus excretion in smallpox. 1. Excretion in the throat, urine, and conjunctiva of patients. Bull World Health Organ (1973) 2.22
Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis (2008) 2.00
Smallpox: clinical and epidemiologic features. Emerg Infect Dis (1999) 1.95
Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol (1990) 1.94
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother (2006) 1.92
Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology (2005) 1.89
Vaccinia virus motility. Annu Rev Microbiol (2003) 1.88
Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg (2007) 1.86
Vaccinia virus morphogenesis and dissemination. Trends Microbiol (2008) 1.73
Respiratory infection of mice with vaccinia virus. J Gen Virol (1967) 1.67
Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo. J Gen Virol (1985) 1.62
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother (2009) 1.52
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res (2008) 1.50
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J Gen Virol (2003) 1.43
Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother (2008) 1.24
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol (2008) 1.22
In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother (2008) 1.19
Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther (2007) 1.17
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine (2007) 0.98
Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: an investigation of potential fomites in the home environment. Vaccine (2008) 0.97
Risk of vaccinia transfer to the hands of vaccinated persons after smallpox immunization. Clin Infect Dis (2004) 0.91
Addition of a photocrosslinking amino acid to the genetic code of Escherichiacoli. Proc Natl Acad Sci U S A (2002) 3.77
Molecular viral oncology of hepatocellular carcinoma. Oncogene (2003) 3.58
Phase transitions in the assembly of multivalent signalling proteins. Nature (2012) 3.49
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol (2005) 3.36
Addition of p-azido-L-phenylalanine to the genetic code of Escherichia coli. J Am Chem Soc (2002) 2.88
High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci (2005) 2.32
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
An expanded genetic code with a functional quadruplet codon. Proc Natl Acad Sci U S A (2004) 2.09
Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med (2014) 2.07
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007) 2.01
Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis (2008) 2.00
Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother (2003) 1.99
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother (2006) 1.92
Spatial dynamics of receptor-mediated endocytic trafficking in budding yeast revealed by using fluorescent alpha-factor derivatives. Proc Natl Acad Sci U S A (2006) 1.86
Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg (2007) 1.86
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
An efficient system for the evolution of aminoacyl-tRNA synthetase specificity. Nat Biotechnol (2002) 1.73
Arp2/3 complex is bound and activated by two WASP proteins. Proc Natl Acad Sci U S A (2011) 1.70
Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. Virol J (2006) 1.69
Generation of a bacterium with a 21 amino acid genetic code. J Am Chem Soc (2003) 1.62
Largest subunits of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors. J Biol Chem (2002) 1.61
The vaccinia virus I7L gene product is the core protein proteinase. J Virol (2002) 1.61
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother (2009) 1.52
Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. Am J Physiol Endocrinol Metab (2008) 1.50
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res (2008) 1.50
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res (2003) 1.44
A phosphorylated pseudokinase complex controls cell wall synthesis in mycobacteria. Sci Signal (2012) 1.41
Arcuate line of the rectus sheath: clinical approach. Anat Sci Int (2008) 1.39
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res (2005) 1.38
Comment on "a new device for cricothyroidotomy". Clin Anat (2006) 1.38
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother (2007) 1.38
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells. Proc Natl Acad Sci U S A (2004) 1.35
Protein arms in the kinetochore-microtubule interface of the yeast DASH complex. Mol Biol Cell (2007) 1.35
Function and structure of a prokaryotic formylglycine-generating enzyme. J Biol Chem (2008) 1.35
Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol (2004) 1.34
Characterization of a family of endogenous neuropeptide ligands for the G protein-coupled receptors GPR7 and GPR8. Proc Natl Acad Sci U S A (2003) 1.33
Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med (2003) 1.32
Structural changes in TAF4b-TFIID correlate with promoter selectivity. Mol Cell (2008) 1.27
Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother (2008) 1.24
Identification of a broad-spectrum arenavirus entry inhibitor. J Virol (2008) 1.23
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol (2008) 1.22
Molecular dissection of the vaccinia virus I7L core protein proteinase. J Virol (2003) 1.20
In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother (2008) 1.19
Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther (2007) 1.17
Escherichia coli DegP protease cleaves between paired hydrophobic residues in a natural substrate: the PapA pilin. J Bacteriol (2002) 1.16
N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors. J Med Chem (2007) 1.13
Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol (2005) 1.12
Requirements for the formation of membrane pores by the reovirus myristoylated micro1N peptide. J Virol (2009) 1.12
Allosteric activation by dimerization of the PknD receptor Ser/Thr protein kinase from Mycobacterium tuberculosis. J Biol Chem (2007) 1.11
Targeted metabolic labeling of yeast N-glycans with unnatural sugars. Proc Natl Acad Sci U S A (2010) 1.08
Listeria monocytogenes 10403S HtrA is necessary for resistance to cellular stress and virulence. Infect Immun (2006) 1.07
New class of orthopoxvirus antiviral drugs that block viral maturation. J Virol (2004) 1.07
Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun (2004) 1.07
Membrane requirement for folding of the herpes simplex virus 1 gB cytodomain suggests a unique mechanism of fusion regulation. J Virol (2012) 1.05
Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol (2011) 1.05
The vaccinia virus G1L putative metalloproteinase is essential for viral replication in vivo. J Virol (2004) 1.04
Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol J (2009) 1.03
Stability and circularization of herpes simplex virus type 1 genomes in quiescently infected PC12 cultures. J Gen Virol (2002) 1.03
Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A (2009) 1.03
The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus. J Virol (2007) 1.02
A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother (2012) 1.02
Conditional expression of vaccinia virus genes in mammalian cell lines expressing the tetracycline repressor. J Virol Methods (2004) 1.01
A conditional-lethal vaccinia virus mutant demonstrates that the I7L gene product is required for virion morphogenesis. Virol J (2005) 1.01
Vaccinia virus proteolysis--a review. Rev Med Virol (2006) 1.00
Vertebral spinal osteophytes. Anat Sci Int (2010) 1.00
Intussusception: an anatomical perspective with review of the literature. Clin Anat (2011) 0.99
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine (2007) 0.98
Phosphorylation of a PDZ domain extension modulates binding affinity and interdomain interactions in postsynaptic density-95 (PSD-95) protein, a membrane-associated guanylate kinase (MAGUK). J Biol Chem (2011) 0.98
Levator glandulae thyroideae muscle with three slips. Anat Sci Int (2008) 0.97
Hepatic aneurysm: a review. Am Surg (2011) 0.97